Sistema de Salut de Catalunya
Institut Català de la Salut
[Álamo MC] Oncology Department, Hospital Universitario Virgen Macarena, Sevilla, Spain. [Ochenduszko S] Oncology Department, Hospital Universitario Dr. Peset, Valencia, Spain. [Crespo G] Oncology Department, Hospital Universitario de Burgos, Burgos, Spain. [Corral M] Oncology Department, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain. [Oramas J] Oncology Department, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain. [Sancho P] Oncology Department, Hospital Universitario Virgen del Rocío, Sevilla, Spain. [Muñoz-Couselo E] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
Vall d'Hebron Barcelona Hospital Campus
2022-05-13T12:39:16Z
2022-05-13T12:39:16Z
2021-11-27
BRAF; Cobimetinib; Vemurafenib
BRAF; Cobimetinib; Vemurafenib
BRAF; Cobimetinib; Vemurafenib
Background: The combination of BRAF and MEK inhibitors delays the onset of resistance and provides more sustained and dramatic responses in comparison with a BRAF inhibitor in monotherapy. The objective of the study was to evaluate the effectiveness of the combination therapy with vemurafenib/cobimetinib in terms of durability, and to describe differential characteristics in patients associated to durable responses in real-world settings. Patients and Methods: Retrospective, observational, cross-sectional, multicenter study involving 41 patients with advanced melanoma harboring a BRAFV600 mutation who initiated a combination therapy with vemurafenib/cobimetinib between May 2018 and March 2019. Participants were differentiated regarding the durability of the response: durable (complete response, CR, or a partial response, PR, for at least 12 months) and non-durable (stable disease, SD, progressive disease, PD, or CR/PR < 12 months). Secondary endpoints included treatment adherence, labor productivity, anxiety/depression, and safety profile. Results: During the combination therapy, 12 patients (29.3%) had a CR, 19 a PR (46.3%), 5 showed SD (12.2%), and 5 had PD. A total of 12 patients (29.3%) were considered as achieving a durable response and 29 (70.7%) as a non-durable one. Practically all sociodemographic and clinical characteristics were similar between patients. Body mass index was the only differential factor (with higher body mass index achieving a non-durable response). The treatment adherence was 100% in patients with durable response and 66.7% in those with non-durable. Conclusion: The combination treatment with vemurafenib/cobimetinib results in an important impact on long-term survival, leading to a steady CR in one-third of the patients.
This study was sponsored and funded by Roche Farma S.A. Spain.
Article
Versió publicada
Anglès
Melanoma - Tractament; Metàstasi; Avaluació de resultats (Assistència sanitària); DISEASES::Neoplasms::Neoplasms by Histologic Type::Neoplasms::Neoplasms by Histologic Type::Neoplasms::Neoplasms by Histologic Type::Nevi and Melanomas::Melanoma; Other subheadings::Other subheadings::Other subheadings::/drug therapy; DISEASES::Neoplasms::Neoplastic Processes::Neoplasm Metastasis; ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis::Treatment Outcome; ENFERMEDADES::neoplasias::neoplasias por tipo histológico::neoplasias::neoplasias por tipo histológico::neoplasias::neoplasias por tipo histológico::nevos y melanomas::melanoma; Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia; ENFERMEDADES::neoplasias::procesos neoplásicos::metástasis neoplásica; TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico::resultado del tratamiento
Dove Medical Press
OncoTargets and Therapy;14
https://doi.org/10.2147/OTT.S325208
Attribution-NonCommercial 4.0 International
http://creativecommons.org/licenses/by-nc/4.0/
Articles científics - HVH [3440]
